Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) EBT (2016 - 2025)

Protalix BioTherapeutics has reported EBT over the past 16 years, most recently at -$197000.0 for Q4 2025.

  • Quarterly results put EBT at -$197000.0 for Q4 2025, down 101.66% from a year ago — trailing twelve months through Dec 2025 was -$1.0 million (down 111.82% YoY), and the annual figure for FY2025 was -$1.0 million, down 111.82%.
  • EBT for Q4 2025 was -$197000.0 at Protalix BioTherapeutics, down from $2.2 million in the prior quarter.
  • Over the last five years, EBT for PLX hit a ceiling of $19.6 million in Q2 2023 and a floor of -$22.1 million in Q4 2023.
  • Median EBT over the past 5 years was -$3.1 million (2022), compared with a mean of -$2.1 million.
  • Biggest five-year swings in EBT: crashed 2179.87% in 2021 and later soared 468.34% in 2023.
  • Protalix BioTherapeutics' EBT stood at -$6.6 million in 2021, then soared by 51.47% to -$3.2 million in 2022, then crashed by 587.01% to -$22.1 million in 2023, then soared by 153.8% to $11.9 million in 2024, then crashed by 101.66% to -$197000.0 in 2025.
  • The last three reported values for EBT were -$197000.0 (Q4 2025), $2.2 million (Q3 2025), and $661000.0 (Q2 2025) per Business Quant data.